Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) is a clinical-stage oncology company whose news flow centers on the development of TERN-701, a highly selective, oral, allosteric BCR-ABL (BCR::ABL1) inhibitor for chronic myeloid leukemia (CML). Company updates describe TERN-701 as the lead program in a focused oncology pipeline, with detailed disclosures on clinical data, regulatory interactions and trial design.
News about Terns frequently highlights results from the CARDINAL trial (NCT06163430), a global multicenter Phase 1/2 study of TERN-701 in previously treated chronic phase CML. Press releases and related SEC filings summarize major molecular response (MMR) and deep molecular response (DMR) rates, safety and tolerability findings, and outcomes in heavily pretreated or difficult-to-treat patient subgroups, including those with prior exposure to other tyrosine kinase inhibitors.
Investors following TERN can also find announcements about regulatory milestones, such as U.S. FDA Fast Track designation for TERN-701 in CML, and information on anticipated clinical priorities and program milestones. Terns’ news includes details on scientific presentations at major conferences like the American Society of Hematology (ASH) Annual Meeting and other healthcare conferences where updated CARDINAL data and development plans are discussed.
In addition, Terns issues news on capital markets activity, including underwritten public offerings of common stock intended to support research, clinical trials, development and manufacturing of key product candidates. Corporate updates may also cover decisions regarding legacy metabolic programs, such as TERN-501, TERN-801 and TERN-601, and the company’s strategy to seek partners for these assets. This news page aggregates such disclosures, offering a centralized view of Terns Pharmaceuticals’ clinical progress, financial developments and strategic focus in oncology.
Terns Pharmaceuticals (Nasdaq: TERN) announced on April 27, 2026 that the FDA granted Breakthrough Therapy Designation to TERN-701, an oral allosteric BCR::ABL1 inhibitor, for adult Ph+ chronic myeloid leukemia in chronic phase without the T315I mutation previously treated with two or more TKIs.
Designation cites encouraging Phase 1/2 CARDINAL data showing rates of major molecular response and deep molecular response at week 24, responses in patients with high baseline disease burden, and a generally low incidence of severe adverse events. The company noted a recent agreement for Merck to acquire Terns.
Merck (NYSE: MRK) announced the Hart-Scott-Rodino Act waiting period in connection with its pending acquisition of Terns Pharmaceuticals (Nasdaq: TERN) expired at 11:59 p.m. ET on April 23, 2026. Merck previously commenced a cash tender offer to buy all outstanding Terns shares for $53.00 net per share.
The expiration of the HSR waiting period satisfies one required condition for consummating the tender offer; closing remains subject to additional conditions in the Schedule TO, including receipt of tenders representing more than 50% of Terns outstanding shares.
Merck (NYSE: MRK) has commenced a cash tender offer to acquire Terns Pharmaceuticals (Nasdaq: TERN) at $53.00 per share. The offer expires one minute after 11:59 p.m. ET on May 4, 2026, and the transaction is expected to close in Q2 2026.
The closing is conditional on the tender of more than 50% of outstanding Terns shares, completion of the Hart-Scott-Rodino waiting period, and customary closing conditions. Upon successful closing, Terns will become a wholly owned subsidiary of Merck.
Terns Pharmaceuticals (Nasdaq: TERN) granted inducement equity awards to three new employees effective April 1, 2026. The Compensation Committee approved a total of 23,316 restricted stock units (RSUs) under the 2022 Employment Inducement Award Plan, vesting over four years subject to continued service.
The awards were made in accordance with Nasdaq Listing Rule 5635(c)(4) as material inducements to accept employment with the company.
Summary not available.
Merck (NYSE: MRK) agreed to acquire Terns Pharmaceuticals for $53.00 per share, valuing Terns at approximately $6.7 billion (about $5.7 billion net of acquired cash) with an expected close in Q2 2026.
The deal adds TERN-701, an oral allosteric BCR::ABL1 TKI in Phase 1/2 for certain CML patients with prior TKI exposure; TERN-701 has FDA Orphan Drug Designation (March 2024) and showed encouraging molecular responses by week 24. Merck expects a ~$5.8 billion charge (≈$2.35/share) in Q2 and full-year 2026 results; the transaction is subject to customary closing conditions and regulatory clearance.
Terns Pharmaceuticals (NASDAQ: TERN) said senior management will participate in multiple investor conferences in March 2026, including TD Cowen, Leerink, Barclays, and The Citizens Life Sciences conferences. Live fireside chat webcasts and replays will be available on the company's investor relations site for at least 30 days.
Terns Pharmaceuticals (Nasdaq: TERN) granted equity inducement awards to two new employees effective February 1, 2026 under its 2022 Employment Inducement Award Plan.
The company approved options to purchase 113,500 shares in aggregate, with a 10-year term, exercise price of $34.60, and standard four‑year vesting subject to continued service.
Terns Pharmaceuticals (Nasdaq: TERN) will present 2026 priorities and program milestones at J.P. Morgan on Jan 12, 2026.
Key points: TERN-701 is in the CARDINAL Phase 1/2 trial with 85+ patients enrolled as of Dec 8, 2025; pivotal dose selection and an End of Phase 2 meeting with the FDA are planned in mid-2026; updated CARDINAL data expected 2H26; initiation of a 2L+ pivotal trial is planned in late 2026/early 2027. TERN-701 received FDA Fast Track designation in Q4 2025. CARDINAL safety and efficacy highlights at ASH: MMR 75% (18/24) by 24 weeks at >320mg QD, DMR 36% (10/28), 87% (55/63) on treatment, grade ≥3 neutropenia 8% and thrombocytopenia 8%. Year-end 2025 cash and marketable securities ≈ $1.0 billion, expected runway into 2031.
Terns Pharmaceuticals (Nasdaq: TERN) announced on January 2, 2026 that it granted inducement equity awards to two new employees under its 2022 Employment Inducement Award Plan.
The company granted options to purchase a total of 312,000 shares of common stock, with a 10-year term and an exercise price of $40.40 per share (the closing price on December 31, 2025). The options vest over four years, subject to continued service, and were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).